MCID: CTN003
MIFTS: 53

Cutaneous Lupus Erythematosus

Categories: Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 72 49 36 14
Lupus Erythematosus, Cutaneous 49 69
Lupus Erythematosus Cutaneous 51

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 36 H01595
UMLS 69 C0024137

Summaries for Cutaneous Lupus Erythematosus

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and lupus erythematosus, and has symptoms including pruritus and exanthema. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Hydroxychloroquine and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Lupus erythematosus tumidus.

Wikipedia : 72 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Subacute Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 34.4 EEA1 TNF TRIM21
2 lupus erythematosus 30.7 CD40LG TNF TREX1 TRIM21 TROVE2
3 chilblain lupus 1 30.2 MX1 TREX1 TRIM21
4 sialadenitis 29.8 TNF TRIM21
5 sjogren syndrome 29.6 CXCR3 TRIM21 TROVE2
6 lymphadenitis 29.3 CXCR3 ICAM1 IL18 TNF
7 actinic prurigo 29.3 ICAM1 SELE TNF
8 alopecia areata 29.2 GZMB ICAM1 TNF
9 psoriasis 29.0 CXCR3 ICAM1 IL18 SELE TNF
10 erythema multiforme 29.0 CXCR3 GZMB ICAM1 TNF
11 vasculitis 29.0 CD40LG ICAM1 SELE TNF
12 rheumatoid arthritis 29.0 CD40LG ICAM1 IL18 TNF
13 lichen planus 28.7 CXCR3 GZMB ICAM1 MX1 TNF
14 systemic lupus erythematosus 27.0 CD40LG CXCR3 ICAM1 IL18 MX1 SELE
15 lupus erythematosus tumidus 11.7
16 systemic onset juvenile idiopathic arthritis 10.5 IL18 TNF
17 listeria meningitis 10.4 IL18 TNF
18 stachybotrys chartarum 10.4 IL18 TNF
19 orofacial granulomatosis 10.4 CXCR3 TNF
20 inflammatory bowel disease 3 10.3 IL18 TNF
21 scleritis 10.3 SELE TNF
22 retinitis pigmentosa 60 10.3 SELE TNF
23 lichen sclerosus 10.3 GZMB TNF
24 cat-scratch disease 10.3 CD40LG EEA1
25 trench fever 10.2 CD40LG TNF
26 rheumatoid lung disease 10.2 CD40LG TNF
27 third-degree atrioventricular block 10.2 TRIM21 TROVE2
28 bartonellosis 10.2 CD40LG EEA1
29 miller fisher syndrome 10.2 CD40LG TNF
30 mycobacterium tuberculosis 1 10.2 CXCR3 IL18 TNF
31 bacterial conjunctivitis 10.2 CD40LG KRT15
32 heart block, congenital 10.2 TRIM21 TROVE2
33 necrotizing ulcerative gingivitis 10.2 CD40LG IL18
34 panencephalitis, subacute sclerosing 10.2 CD40LG MX1
35 dermatomyositis 10.2
36 schnitzler syndrome 10.2 CD40LG IL18
37 hyperglobulinemic purpura 10.2 CD40LG TRIM21
38 central nervous system vasculitis 10.2 CD40LG TNF
39 facial hemiatrophy 10.2 CD40LG TRIM21
40 osteosclerotic myeloma 10.2 CD40LG TNF
41 t-cell large granular lymphocyte leukemia 10.1 GZMB IL18
42 rasmussen encephalitis 10.1 GZMB IL18 TNF
43 acute graft versus host disease 10.1 GZMB IL18 TNF
44 discoid lupus erythematosus 10.1
45 peripheral t-cell lymphoma 10.1 CXCR3 GZMB
46 african tick-bite fever 10.1 CD40LG SELE
47 hemophagocytic lymphohistiocytosis 10.1 GZMB IL18 TNF
48 encephalitozoonosis 10.1 CD40LG MX1 TNF
49 bronchiolitis obliterans 10.1 CXCR3 GZMB TNF
50 arthritis 10.1

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


pruritus, exanthema

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CD40LG GZMB ICAM1 IL18 MX1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CD40LG GZMB ICAM1 IL18 MX1 TNF

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 CD40LG CXCR3 ICAM1 IL18 SELE TNF
2 immune system MP:0005387 9.61 CD40LG CXCR3 ICAM1 IL18 SELE TNF
3 integument MP:0010771 9.23 CD40LG ICAM1 IL18 SELE TNF TREX1

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 3 118-42-3 3652
2 Antirheumatic Agents Phase 3,Phase 2,Phase 1
3 Dermatologic Agents Phase 3,Phase 2
4 Anti-Infective Agents Phase 3,Phase 2
5 Antimalarials Phase 3
6 Antiparasitic Agents Phase 3
7 Antiprotozoal Agents Phase 3
8 Protective Agents Phase 3
9 Radiation-Protective Agents Phase 3
10 Sunscreening Agents Phase 3
11
Etanercept Approved, Investigational Phase 2 185243-69-0
12
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
13
Norflurane Approved, Investigational Phase 2 811-97-2
14
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 5271565 637568
15
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
16
Tofacitinib Approved, Investigational Phase 1, Phase 2,Early Phase 1 477600-75-2
17
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
20
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
21
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538
22
Cholecalciferol Approved, Nutraceutical Phase 2 67-97-0 10883523 5280795 6221
23
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
25 Antibodies Phase 1, Phase 2, Early Phase 1
26 Antibodies, Monoclonal Phase 1, Phase 2
27 Immunoglobulins Phase 1, Phase 2, Early Phase 1
28 Analgesics Phase 2,Phase 1
29 Analgesics, Non-Narcotic Phase 2,Phase 1
30 Anti-Inflammatory Agents Phase 2,Phase 1
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1
32 Gastrointestinal Agents Phase 2
33 Immunosuppressive Agents Phase 2
34 Peripheral Nervous System Agents Phase 2,Phase 1
35 Calcineurin Inhibitors Phase 2
36 Phosphodiesterase 4 Inhibitors Phase 1, Phase 2
37 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
38 Phosphodiesterase Inhibitors Phase 1, Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Angiogenesis Modulating Agents Phase 2
41 Anti-Bacterial Agents Phase 2
42 Antimetabolites Phase 2
43 Hypolipidemic Agents Phase 2
44 Lipid Regulating Agents Phase 2
45 Micronutrients Phase 2
46 Nicotinic Acids Phase 2
47 Trace Elements Phase 2
48 Vasodilator Agents Phase 2
49 Vitamin B Complex Phase 2
50 Vitamins Phase 2

Interventional clinical trials:

(show top 50) (show all 58)

# Name Status NCT ID Phase Drugs
1 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
2 Sunscreen RV 2457C in Photoinduced CLE Completed NCT00470912 Phase 3 sunscreen RV 2547C
3 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
4 Phase Ib Study of SC Milatuzumab in SLE Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
5 The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus Unknown status NCT00797784 Phase 2 etanercept(Enbrel®)
6 Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Completed NCT00523588 Phase 2
7 Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
8 To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
9 Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) Completed NCT00317681 Phase 2 Tacrolimus ointment
10 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Completed NCT01352988 Phase 2 Fumaric acid esters
11 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed NCT00708916 Phase 1, Phase 2 CC-10004
12 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
13 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus Completed NCT02437890 Phase 2
14 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Completed NCT01597050 Phase 2 R932333;Placebo
15 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions Completed NCT00625521 Phase 2 ASF 1096 0.5 % cream applied twice daily;Cream vehicle for ASF 1096 cream applied twice daily
16 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) Completed NCT00625157 Phase 2 ASF 1096 0.5 % cream;ASF 1096 placebo cream
17 A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Completed NCT00001680 Phase 2 Thalidomide
18 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
19 Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Recruiting NCT03134222 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
20 Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus Recruiting NCT03260166 Phase 2 nicotinamide
21 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Recruiting NCT02660944 Phase 2 RSLV-132;Placebo
22 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
23 TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment Recruiting NCT02711813 Phase 2 TAB08
24 Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care Recruiting NCT03371251 Phase 1, Phase 2 BOS161721;Placebo
25 A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE) Recruiting NCT02975336 Phase 2 Placebo;M2951;M2951;M2951
26 Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Active, not recruiting NCT02656082 Phase 2 Etanercept
27 An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus Active, not recruiting NCT03252587 Phase 2 BMS-986165
28 Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus Not yet recruiting NCT03451422 Phase 1, Phase 2 AMG 592;Placebo
29 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Terminated NCT01407679 Phase 2 Alitretinoin
30 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
31 A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus Terminated NCT01466725 Phase 2 CC-930;Placebo
32 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Terminated NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
33 Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva Terminated NCT00308204 Phase 2 Raptiva (efalizumab)
34 A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
35 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Patients Recruiting NCT02927457 Phase 1 GSK2646264 1%;Placebo
36 Autologous Polyclonal Tregs for Lupus Active, not recruiting NCT02428309 Phase 1
37 A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Terminated NCT01470313 Phase 1 PD-0360324;Placebo
38 Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo
39 Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus Terminated NCT01164917 Phase 1 AMG811;AMG811 Placebo
40 Cutaneous Lupus Erythematosus and Elidel Unknown status NCT00222183 Elidel (pimecrolimus)
41 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Unknown status NCT01559155
42 IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus Completed NCT01841619 Early Phase 1 IVIg
43 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784
44 Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) Completed NCT00633945 lenalidomide (Revlimid®)
45 Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) Completed NCT01146444
46 A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Completed NCT02034344 Early Phase 1
47 Interdisciplinary Study Group of Lupus Erythematosus (ISGLE) Completed NCT00420173
48 A Non-drug Study Profiling Cutaneous Lupus Completed NCT01923415 Early Phase 1
49 Pilot Tape Harvesting Study Completed NCT02125695
50 A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies Completed NCT01858792 Belimumab 1 mg/kg;Belimumab 10 mg/kg

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

38
Skin, Lung, Heart, Kidney, T Cells, Bone, Breast

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 745)
# Title Authors Year
1
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( 28989111 )
2018
2
Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. ( 29423919 )
2018
3
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. ( 29061479 )
2018
4
Subacute cutaneous lupus erythematosus presenting in twins. ( 29436018 )
2018
5
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. ( 29307217 )
2018
6
Subacute cutaneous lupus erythematosus: is clopidogrel a trigger? ( 29327459 )
2018
7
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. ( 29349515 )
2018
8
Cutaneous lupus erythematosus: clinico-pathologic correlation. ( 29368845 )
2018
9
Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study. ( 28618892 )
2017
10
The deposition of anti-DNA IgG contributes to the development of cutaneous lupus erythematosus. ( 28899632 )
2017
11
Rowell's Syndrome or subacute cutaneous lupus erythematosus? ( 27978611 )
2017
12
Subacute cutaneous lupus erythematosus induced by nivolumab. ( 28726325 )
2017
13
Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands. ( 28331627 )
2017
14
Results of lumbar puncture, CT and MRI in a case of quinacrine-induced psychosis involving a patient with cutaneous lupus erythematosus. ( 28540035 )
2017
15
Dyschromatosis symmetrica hereditaria with cutaneous lupus erythematosus and hyperthyroidism. ( 28496371 )
2017
16
An update in drug-induced subacute cutaneous lupus erythematosus. ( 28329511 )
2017
17
Chronic cutaneous lupus erythematosus revealed by unilateral eyelid oedema. ( 28943504 )
2017
18
Nuclear proteins and apoptotic bodies are found in the lupus band of patients with cutaneous lupus erythematosus. ( 28842330 )
2017
19
Quinacrine Suppresses Tumor Necrosis Factor-I+ and IFN-I+ in Dermatomyositis andA Cutaneous Lupus Erythematosus. ( 28941496 )
2017
20
From Paris to Vienna-The Varied Names and Descriptions of Cutaneous Lupus Erythematosus in the 19th Century. ( 29049558 )
2017
21
Bizarre appearance of chronic cutaneous lupus erythematosus of face mimicking factitial dermatitis. ( 29224226 )
2017
22
Chronic cutaneous lupus erythematosus presenting as atypical acneiform and comedonal plaque: case report and literature review. ( 28857716 )
2017
23
High Expression of B Lymphocyte Stimulator (BLyS) in Lesional Keratinocytes of Patients with Cutaneous Lupus Erythematosus. ( 28833566 )
2017
24
Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90A Patients at Mayo Clinic, 1996-2011. ( 28185656 )
2017
25
Imiquimod-induced cutaneous lupus erythematosus with antinuclear antibodies showing a homogenous pattern. ( 28616880 )
2017
26
Subacute cutaneous lupus erythematosus - paraneoplastic to gastric adenocarcinoma? ( 28421344 )
2017
27
A Cutaneous Lupus Erythematosus-Like Eruption Induced by Hydroxyurea. ( 27813209 )
2017
28
The Histopathological Spectrum of Pseudolymphomatous Infiltrates in Cutaneous Lupus Erythematosus. ( 28654469 )
2017
29
Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus. ( 28862574 )
2017
30
Pigmented macular variant of chronic cutaneous lupus erythematosus: an under-recognized subset in dark skin. ( 28590034 )
2017
31
Histologic features of chronic cutaneous lupus erythematosus of the scalp using horizontal sectioning: Emphasis on follicular findings. ( 28624120 )
2017
32
Cutaneous Lupus Erythematosus Presenting as Frontal Fibrosing Alopecia: Report of 2 Patients. ( 29177150 )
2017
33
Cutaneous lupus erythematosus. Quality of life and related factors in a cohort of 260 patients of A CoruA+a, Spain. ( 28832955 )
2017
34
Subacute cutaneous lupus erythematosus induced by masitinib. ( 28940367 )
2017
35
TWEAK/Fn14 Activation Participates in Ro52-Mediated Photosensitization in Cutaneous Lupus Erythematosus. ( 28620393 )
2017
36
The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. ( 28711090 )
2017
37
Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. ( 28480635 )
2017
38
Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus. ( 28636714 )
2017
39
Linear cutaneous lupus erythematosus/discoid lupus erythematosus in an adult. ( 28507499 )
2017
40
The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. ( 26850655 )
2016
41
Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand. ( 27235700 )
2016
42
Cancer risk in cutaneous lupus erythematosus: a population-based cohort study. ( 27520797 )
2016
43
Beside to bench: JAK-inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. ( 27892610 )
2016
44
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). ( 27859683 )
2016
45
Voriconazole-Induced Subacute Cutaneous Lupus Erythematosus in an Adult With Aspergillosis. ( 28031137 )
2016
46
First case of paraneoplastic subacute cutaneous lupus erythematosus associated with colon cancer. ( 27836354 )
2016
47
Dermoscopy of subacute cutaneous lupus erythematosus. ( 27260752 )
2016
48
Bilateral periorbital swelling as the initial presentation of cutaneous lupus erythematosus. ( 27051834 )
2016
49
Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. ( 27249209 )
2016
50
Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. ( 26910509 )
2016

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 CD40LG ICAM1 IL18 MX1 TNF TRIM21
2
Show member pathways
12.58 ICAM1 IL18 MX1 TNF
3 12.02 EEA1 IL18 TNF
4
Show member pathways
11.92 IL18 MX1 TNF
5 11.9 CD40LG ICAM1 SELE
6 11.87 ICAM1 SELE TNF
7 11.73 ICAM1 IL18 TNF
8 11.69 ICAM1 SELE TNF
9 11.63 ICAM1 SELE TNF
10 11.59 CD40LG ICAM1 TNF
11 11.53 ICAM1 IL18 TNF
12 11.46 CXCR3 GZMB IL18 TNF
13 11.36 CD40LG ICAM1 TNF
14
Show member pathways
11.26 CD40LG ICAM1 SELE TNF
15 11.19 ICAM1 IL18 TNF
16 10.97 ICAM1 IL18
17 10.91 IL18 TNF
18 10.8 ICAM1 IL18 SELE TNF
19 10.73 ICAM1 TNF
20 10.71 CD40LG ICAM1 IL18 SELE TNF

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40LG CXCR3 ICAM1 TNF

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.58 CD40LG ICAM1 TNF
2 negative regulation of myoblast differentiation GO:0045662 9.48 IL18 TNF
3 positive regulation of NF-kappaB import into nucleus GO:0042346 9.46 IL18 TNF
4 natural killer cell mediated cytotoxicity GO:0042267 9.43 GZMB IL18
5 regulation of type I interferon production GO:0032479 9.37 TREX1 TRIM21
6 inflammatory response GO:0006954 9.35 CD40LG CXCR3 IL18 SELE TNF
7 leukocyte tethering or rolling GO:0050901 9.32 SELE TNF
8 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.26 ICAM1 TNF
9 regulation of immunoglobulin secretion GO:0051023 9.16 CD40LG TNF
10 leukocyte cell-cell adhesion GO:0007159 8.8 CD40LG ICAM1 SELE

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....